Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC + Bevacizumab in HER2+ Advanced Colorectal Cancer
NCT05785325Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2023
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in colorectal cancer (CRC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate up to 18 months. Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05785325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05785325.